Video Series: Current Topics in the Treatment of Advanced PCa

Targeted Agents

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.

Latest Prostate Cancer Features

Latest Prostate Cancer News

Tasquinimod Improves Radiographic Progression-Free Survival in mCRPC

Tasquinimod Improves Radiographic Progression-Free Survival in mCRPC

Does not improve overall survival in metastatic castration-resistant prostate cancer.

PSA of 0.4 ng/mL Predicts PCa Progression

PSA of ≥0.4 ng/mL Predicts PCa Progression

Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.

Midlife PSA Levels Predict Lethal Prostate Cancer

Midlife PSA Levels Predict Lethal Prostate Cancer

The odds of developing lethal prostate cancer were increased by 6.9 to 12.6 times for men aged 40 to 59 years with higher PSA values.

Record Numbers of Americans Are Cancer Survivors

Record Numbers of Americans Are Cancer Survivors

More effective tools are needed to support the long-term recovery of patients who survive cancer.

Many Terminal Cancer Patients Still Receive Aggressive Treatment

Many Terminal Cancer Patients Still Receive Aggressive Treatment

Three in 4 young or middle-aged patients receive aggressive therapies in the last months of life.

Adjuvant Docetaxel Does Not Help Biochemical DFS in High-risk PCa

Adjuvant Docetaxel Does Not Help Biochemical DFS in High-risk PCa

In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.

TRUS-biopsy Inferior for Prostate Cancer Detection

TRUS-biopsy Inferior for Prostate Cancer Detection

Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.

Enzalutamide-Abiraterone-Leuprolide Ineffective for Localized PCa

Enzalutamide-Abiraterone-Leuprolide Ineffective for Localized PCa

Adding enzalutamide to abiraterone acetate and leuprolide acetate does not appear to be effective for the treatment of localized high-risk prostate cancer.

Model Predicts Chemotherapy Toxicity in Solid Tumor Patients

Model Predicts Chemotherapy Toxicity in Solid Tumor Patients

A predictive model for chemotherapy toxicity found that 58% of patients experienced grade 3 toxicity or higher.

Factors Affecting Post-Brachytherapy Urinary Incontinence Type ID'd

Factors Affecting Post-Brachytherapy Urinary Incontinence Type ID'd

TURP and EBRT after seed implantation are associated with development of urge urinary incontinence.

Androgen Suppression With Salvage Radiotherapy May Fight Progression

Androgen Suppression With Salvage Radiotherapy May Fight Progression

Adding short-term androgen suppression to salvage radiotherapy may benefit men with prostate cancer who have undergone radical prostatectomy.

Localized PCa Patients Misperceive Their Odds of Survival

Localized PCa Patients Misperceive Their Odds of Survival

Most patients have unrealistic survival expectations, which may compromise their ability to make informed treatment decisions.

Local Therapy Benefits Some Metastatic PCa Patients

Local Therapy Benefits Some Metastatic PCa Patients

Patients with a relatively low tumor risk and good general health status appear to experience the best survival.

Prostate, Bladder Cancer Linked to BPH

Prostate, Bladder Cancer Linked to BPH

In a meta-analysis, men with benign prostatic hyperplasia had a 2.9 times and 1.7 times increased incidence of prostate cancer and bladder cancer, respectively.

Prognostic Cancer Screening Tools Show Promise

Prognostic Cancer Screening Tools Show Promise

High rates of screening for individuals with limited long-term life expectancy for all tools.

Prostate Cancer Videos

Sign up for free e-Newsletters